Indivior Pharmaceuticals, Inc. - Form 8-K Filing

Indivior Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2026, on April 30, 2026. The company announced a total net revenue of $317 million, a 19% increase year-over-year, with SUBLOCADE® net revenue reaching $232 million, up 32% year-over-year. Q1 2026 GAAP net income was $89 million, and non-GAAP net income was $123 million. Adjusted EBITDA reached a record $164 million, an 112% increase year-over-year. Indivior also raised its full-year 2026 financial guidance, expecting total SUBLOCADE net revenue growth of 13% and adjusted EBITDA growth of 50% year-over-year. The company repurchased approximately four million shares for $125 million in Q1 2026 and completed a $500 million convertible senior notes offering. Indivior is progressing through Phase II of its Action Agenda, focusing on accelerating SUBLOCADE growth and improving profitability.